Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A small clinical trial showed that cancer drug Nilotinib may reverse late-stage Parkinson’s disease, potentially enabling participants to speak and walk again for the first time in years.

President and co-founder of The Cure Parkinson’s Trust, Tom Isaacs, has called for a close follow up of this small study to ensure that any opportunity for a breakthrough in the treatment of Parkinson’s is not missed.

Isaacs said: ‘Nilotinib is a case in point. When people with Parkinson’s volunteer for clinical trials and feel the type of marked improvements to their symptoms and wellbeing as those reported in this study, we owe it to them, and indeed everyone, to follow the results up as quickly and as rigorously as possible.”

Go Back

Share this story

Comments


Related articles


DBS Image

sponsored article

Advances

VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients

Technological advancements offer enhanced therapy outcomes

READ MORE

Perspectives

Tonya’s trends: ‘off the shoulder’ – a low-slung look on the up

This season’s off the shoulder trend hides DBS surgery scars

READ MORE
The cast and crew of the film 'STAGES' stand aside the film poster

Europe

STAGES: “an honest and human portrayal of Parkinson’s”

We hear what the cast and crew learnt about the condition

READ MORE